Register Now
Why register?
Login
 The leading web portal for pharmacy resources, news, education and careers August 22, 2017
Pharmacy Choice - Pharmacy News - August 22, 2017

Pharmacy News

Today's Pharmaceutical and Pharmacy News
Daily News Topic:

FDA News
8/22/17 - Aurobindo Pharma gets USFDA nod for anti-HIV drug [Arab News (Saudi Arabia)]
Aurobindo Pharma has received tentative approval from the USFDA for dolutegravir, lamivudine and tenofovir disoproxil fumarate tablets, used for the treatment of HIV, in the US market. In a BSE filing, Aurobindo Pharma said it has received "tentative approval from the US Food and Drug Administration under the US President`s Emergency Plan For AIDS
8/22/17 - B. Braun Launches New Dialyzer
B. Braun Medical issued the following news release:. B. Braun Medical Inc. today announced that the U.S. Food and Drug Administration has cleared its hemodialyzer, Diacap (R) Pro. "The newly developed fibers in Diacap Pro are designed to improve dialysis dose," said Samuel Amory, Vice President at B. Braun Medical.
8/22/17 - BESPONSA® (inotuzumab ozogamicin) Approved for Treatment of Adult Relapsed or Refractory B-cell Precursor Acute Lymphoblastic Leukemia, Available for Order at Biologics, Inc.
Biologics, Inc., a McKesson Specialty Health oncology pharmacy services company, announced today it has been selected by Pfizer, Inc. to be a specialty pharmacy provider for BESPONSA ®, a promising new IV therapy for adult patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia. Approved by the U.S. Food and Drug Adminis
8/22/17 - FDA Approves IRWD's Gout Drug, It's A Thumbs Up For ALXN In EU, CRME Crushed
TOKYO- Today's Daily Dose brings you news about European approval of Alexion' s Soliris for an additional indication; Alkermes' New Drug Application for a major depressive disorder drug; Astellas' MORPHO trial progress; Axovant's move to NASDAQ from the Big Board; Cardiome's disappointing update related to its antiarrhythmic drug and FDA approval o
8/22/17 - FDA evaluates prescription opioid medications approved for children
The FDA has heard from professional groups, including the American Academy of Paediatrics about the use of opioid cough suppressants for children...
8/22/17 - Ironwood Pharmaceuticals Announces FDA Approval of DUZALLO for the Treatment of Hyperuricemia in Patients with Uncontrolled Gout
Release date- 21082017- CAMBRIDGE, Mass.- Ironwood Pharmaceuticals, Inc. today announced DUZALLO was approved by the U.S. Food and Drug Administration as a once daily oral treatment for hyperuricemia associated with gout in patients who have not achieved target serum uric acid levels with a medically appropriate daily dose of allopurinol alone.

Chain Drug Review
Chain Drug Review Magazine Chain Drug Review, established in 1978 and published 21 times a year, is recognized as the premier news publication serving the entire chain drug store industry.
Featured Article from Chain Drug Review:
AWP suit settlement appealed
The National Association of Chain Drug Stores has appealed a U.S. District Court’s approval of settlements in the First DataBank Inc. and Medi-Span Inc. lawsuit. »read more

Pharmacy News Index
  Drug Delivery Systems
  Drugstores
  FDA Final Approvals
  Front Page Healthcare News
  Generic Drugs
  Hospital Industry
  Internet Pharmacy
  IT in Healthcare
  Medicare & Medicaid
  Over-the-Counter Drugs
  Pharm Industry Trends and Policy
  Pharmaceutical Development
  Pharmaceutical Industry

FEATURED CE LESSON

Legal & Practical Issues in Compounding Pharmacy
This lesson is supported by:
RxSchool
Men's Health in Older Adults: Benign Prostatic Hyperplasia and Erectile Dysfunction
This lesson is supported by:
RxSchool
Pharmacy Spanish
This lesson is supported by:
RxSchool
Drug Therapy Management Series Part III: Geriatric Disorders
This lesson is supported by:
RxSchool

Special Announcement

Free Membership
Enjoy Drug Search, industry newsletters and more...


Websites » RxCareerCenter.comRxSchool.comClubStaffing.comNursingJobSource.comRN.com
Copyright © 2017 Pharmacy Choice - All rights reserved.
Terms and Conditions | Privacy Statement
888-682-4415